Vertex Pharmaceuticals' Trikafta gained FDA approval for children 2 and older with cystic fibrosis, now addressing 94 mutations and including a warning regarding potential liver injury.
Barclays has maintained an Equal-Weight rating on Vertex Pharmaceuticals Incorporated (VRTX) while reducing its price target from $509.00 to $418.00 per share.